Abstract
Objective:
An endogenous digitalis-like factor (EDLF) has been implicated in the pathophysiology of preeclampsia (PE). This hypothesis is supported by two cases of preeclampsia in which administration of digoxin immune Fab (DIF) reduced mean arterial pressure (MAP).
Study Design:
To study this observation further, we performed a double-blind, placebo-controlled, randomized clinical trial to examine the effects on MAP of intravenous DIF given after delivery in 26 subjects with severe preeclampsia. Treating obstetricians were blinded to subject assignment and were allowed to use standard antihypertensive drugs during the trial.
Results:
The primary outcome, a significant difference in blood pressure between the two groups over the 24-h period of observation after the intervention, was not supported. However, mean MAP was significantly lower in the DIF-treated subjects for the first 4 h after therapy as compared with controls (P=0.05). Six subjects (46.2%) in the placebo arm were given conventional antihypertensive medications by their obstetrician for blood pressure >160 mm Hg systolic or >110 mm Hg diastolic, compared with zero subjects in the treatment arm (P=0.01). A trend towards increased creatinine clearance was observed in DIF-treated subjects (137.6±42.6 versus 104.1±43.4, P=0.07).
Conclusion:
These results support the hypothesis that EDLF contributes to the elevated blood pressure in preeclampsia and suggests a possible role for DIF as a treatment for this condition.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Cunningham FG, MacDonald PC, Grant NF, Leveno KJ, Gilstrap III LC, Hankins GDV et al. Hypertensive disorders in pregnancy. Williams Obstetrics. 20th edn, Appleton S Lange: Stanford, Connecticut, 1997 pp 693–744.
Buckalew Jr VM, Haddy FJ . Endogenous digitalis-like factors in hypertension In: Laraugh JH, Brenner BM (eds). Hypertension, Pathophysiology, Diagnosis and Management. Raven Press: New York, 1995 2nd edn, pp 1055–1067.
De Wardener HE, MacGregor GA . Dahl's hypothesis that a saluretic substance may be responsible for a sustained rise in arterial pressure: Its possible role in essential hypertension. Kidney Int 1980; 18: 1–9.
Graves SW, Williams GH . Endogenous digitalis-like factors. Annu Rev Med 1987; 38: 433–444.
Gusdon JP, Buckalew VM, Hennessy JF . A digoxin-like immunoreactive substance in preeclampsia. AM J Obstet Gynecol 1984; 150: 83–85.
Beyers AD, Odendaal HJ, Spruyt LL, Parkin DP . The possible role of endogenous digitalis-like substance in the causation of preeclampsia. S Afr Med J 1984; 65 (22): 883–885.
Kunes J, Stolba P, Pohlova I, Jelinek J, Zicha J . The importance of endogenous digoxin-like factors in rats with various forms of experimental hypertension. Clin Exp Hypertens 1985; 7 (5–6): 707–720.
Goodlin RC . Will treatment with Digoxin antibody benefit pregnant patients with toxemia and elevated digoxin-like factor? Med Hypotheses 1987; 24: 107–110.
Goodlin RC . Antidigoxin antibodies in eclampsia. N Engl J Med 1988; 318: 518–519.
Adair CD, Buckalew VM, Taylor K, Ernest JM, Frye AH, Evans C et al. Elevated endoxin-like factor complicating a multifetal second trimester pregnancy: Treatment with digoxin-binding immunoglobulin. Am J Nephrol 1996; 16: 529–531.
American College of Obstetricians and Gynecologist. Management of preeclampsia. Technical Bulletin No. 91, February 1986.
Physicians' Desk Reference. (48th ed.). 1994 Oradell, NJ: Medical Economics Co.
Phelps SJ, Cochran EB, Gonzalez-Ruiz RA, Tolley EA, Hammond KD, Sibai BM . The influence of gestational age and preeclampsia on the presence and magnitude of serum endogenous digoxin-like immunoreactive substance(s). Am J Obstet Gynecol 1988; 158: 34–39.
Poston L, Morris JF, Wolfe CD, Hilton PJ . Serum digoxin-like substances in pregnancy-induced hypertension. Clin Sci 1989; 77: 189–194.
Jakobi P, Krivoy N, Weissman A, Paldi E . Digoxin-like immunoreactive factor in twin and pregnancy-associated hypertensive pregnancies. Obstet Gynecol 1989; 74: 29–33.
Kerkez SA, Poston L, Wolfe CD, Quartero HW, Carabelli P, Petruckevitch A et al. A longitudinal study of maternal digoxin-like immunoreactive substances in normotensive pregnancy and pregnancy-induced hypertension. Am J Obstet Gyncol 1990; 162: 783–787.
Kaminski K, Rechberger T . Concentration of digoxin-like immunoreactive substance in patients with preeclampsia and its relation to severity of pregnancy-induced hypertension. Am J Obstet Gynecol 1991; 165: 733–736.
Selly EW, Williams GH, Graves SW . Markers of sodium and volume homeostasis in pregnancy-induced hypertension. J Clin Endocrinal Metab 1992; 74: 150–156.
Graves SW, Valdes Jr R, Brown BA, Knight AB, Craig HR . Endogenous digoxin-immunoreactive substance in human pregnancies. J Clin Endocrinol Met 1984; 58: 748–751.
Magann EF, Perry Jr KG, Meydrech EF, Harris RL, Chauhan SP, Martin Jr JN . Postpartum corticosteroids: accelerated recovery from the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP). Am J Obstet Gynecol 1994; 171 (4): 1154–1158.
Nesher M, Shpolansky U, Rosen H, Lichstein D . The digitalis-like steroid hormones: New mechanisms of action and biological significance. Life Sciences 2007; 80: 2093–2107.
Bagrov AY, Fedorova OV, Dmitrieva RI, French AW, Anderson DE . Plasma marinobufagenin-like and ouabain-like immunoreactivity during saline volume expansion in anesthetized dogs. Cardiovasc Res 1996; 31: 296–305.
Hamlyn JM, Blaustein MP, Bova S, DuCharme DW, Harris DW, Mandel F et al. Identification and characterization of a ouabain-like compound from human plasma. Proc Natl Acad Sci USA 1991; 88: 6259–6263.
Kawamura A, Guo J, Itagaki Y, Bell C, Wang Y, Haupert Jr GT et al. On the structure of endogenous ouabain. Proc Natl Acad Sci USA 1999; 96: 6654–6659.
Bagrov AY, Fedorova OV, Dmitrieva RI, Howald WN, Hunter AP, Kuznetsova EA et al. Characterization of a urinary bufodienolide Na+, K+-ATPase inhibitor in patients after acute myocardial infarction. Hypertension 1998; 31: 1097–1103.
Lopatin DA, Ailamazian EK, Dmitrieva RI, Shpen VM, Fedorova OV, Doris PA et al. Circulation bufodienolide and cardenolide sodium pump inhibitors in preeclampsia. J Hypertens 1999; 17: 1179–1187.
Morris JF, Poston L, Wolfe CD, Hilton PJ . A comparison of endogenous digoxin-like immunoreactivity and sodium transport inhibitory activity in umbilical arterial and venous serum. Clin Sci 1988; 75: 577–579.
Seccombe DW, Pudek MR, Whitfield MF, Jacobson BE, Wittman BK, King JF . Perinatal changes in a digoxin-like immunoreactive substance. Pediatr Res 1984; 18: 1097–1099.
Shrivastav P, Gill DS, D'Souza V, O'Brien PM, Dandona P . Secretion of atrial natriuretic peptide and digoxin-like immunoreactive substance during pregnancy. Clin Chem 1988; 34: 977–980.
Diamandis EP, Papanastasiou-Diamandi A, Soldin SJ . Digoxin immunoreactivity in cord and maternal serum and placental extracts. Partial characterization of immunoreactive substances by high-performance liquid chromatography and inhibition of Na+, K+ATPase. Clin Biochem 1985; 18 (1): 48–55.
Di Grande A, Boura ALA, Read MA, Malatino LS, Walters WAW . Release of a substance from the human placenta having digoxin-like immunoreactivity. Clin Exp Pharmacol Physiol 1993; 20: 603–607.
Hilton PJ, White RW, Lord GA, Garner GV, Gordon DB, Hilton MJ et al. An inhibitor of the sodium pump obtained from human placenta. Lancet 1996; 348 (9023): 303–305.
Magann EF, Martin Jr JN, Issacs JD, Perry Jr KG, Martin RM, Meydrech EF . Immediate postpartum curettage: Accelerated recovery from severe preeclampsia. Obstet Gynecol 1993; 81: 502–506.
Bagrov AY, Fedorova OV, Roukoyatkina NI, Zhabko EP . Effect of endogenous digoxin- like factor and digoxin antibody on myocardial Na+, K+-pump activity and ventricular arrhythmias in acute myocardial ischemia in rats. Cardiovasc Res 1993; 27: 1045–1050.
Schobel HP, Fischer T, Heuszer K, Geiger H, Schmieder RE . Preeclampsia-A state of sympathetic overactivity. N Engl J Med 1996; 335: 1480–1485.
Hayman R, Grockelsby J, Kenny L, Baker P . Preeclampsia: the endothelium, circulating factor(s) and vascular endothelial growth factor. J Soc Gynec Invest 1999; 6 (1): 3–10.
Lam G, Johnson D, Robinson C, Saade G, Lewis D, Porter K et al. Antepartum administration of digoxin immune Fab (Digibind) improves renal function in subjects with severe preeclampsia. Hypertens Pregnancy 2008; 27(4): 422.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Adair, C., Luper, A., Rose, J. et al. The hemodynamic effects of intravenous digoxin-binding fab immunoglobulin in severe preeclampsia: a double-blind, randomized, clinical trial. J Perinatol 29, 284–289 (2009). https://doi.org/10.1038/jp.2008.224
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/jp.2008.224